Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.

Gynecologic oncology - 1 Mar 2020

Jorge Soledad, McFaddin Andrew S, Doll Kemi M, Pennington Kathryn P, Norquist Barbara M, Bennett Robin L, Pritchard Colin C, Swisher Elizabeth M

Abstract excerpt

OBJECTIVE: Germline and somatic BRCA1 and BRCA2 (BRCA) mutations predict treatment response in patients with epithelial ovarian, peritoneal or fallopian tube cancer (OC), yet only germline testing is routinely pursued or reimbursed at diagnosis. We report our experience with clinical testing of paired tumor and germline DNA for OC mutations. METHODS: Simultaneous sequencing using the BROCA assay of DNA from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ovarian Epithelial

Share to Clinical Decision-Making

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Mutation Rate

Share to Neoplasm Recurrence, Local

Source

Identifiers

PMID: 31883735
DOI: 10.1016/j.ygyno.2019.12.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.PMID 31883735Read ↗

Inherited Mutations in Women With Ovarian Carcinoma.Semantic proximity Read ↗

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).Semantic proximity Read ↗

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline SummarySemantic proximity Read ↗

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2Semantic proximity Read ↗

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar populationSemantic proximity Read ↗

BRCA mutations: Implications of genetic testing in ovarian cancer.Semantic proximity Read ↗

Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted TherapySemantic proximity Read ↗

Exploring the somatic mutational landscape of ovarian cancer in Estonia.Semantic proximity Read ↗

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionSemantic proximity Read ↗

Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.Semantic proximity Read ↗

Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.